UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 10-QSB

(Mark One)

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
    ACT OF 1934

                FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2007

                                       OR

[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
    ACT OF 1934

                  FOR THE TRANSITION FROM _______ TO ________.

                       COMMISSION FILE NUMBER: 000-52458


                           ARKSON NUTRACEUTICALS CORP.
        (Exact Name of Small Business Issuer as Specified in its Charter)

          DELAWARE                                               51-0383940
(State or other jurisdiction of                               (I.R.S. Employer
 incorporation or organization)                              Identification No.)

4653 Carmel Mountain Road, Ste. 308-129
       San Diego, California                                        92130
(Address of principal executive offices)                          (Zip code)

                     Issuer's telephone number: 858-459-1133

                                       N/A
              (Former name, former address and former fiscal year,
                         if changed since last report.)

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act).Yes [X] No [ ]

State the number of shares outstanding of each of the issuer's classes of common
equity, for the period covered by this report and as at the latest practicable
date:

     At December 31, 2007, there were outstanding 10,917,780 shares of the
     Registrant's Common Stock, $.0001 par value.

Transitional Small Business Disclosure Format: Yes [ ] No [X]
<PAGE>
                           ARKSON NUTRACEUTICALS CORP.
                        (A Development Stage Enterprise)


ITEM 1. FINANCIAL STATEMENTS

                                                                         Page
                                                                         ----

   Balance Sheets                                                          3

   Statements of Operations                                                4

   Statements of Stockholders' Equity                                      5

   Statements of Cash Flows                                                6

   Notes to Financial Statements                                           7


                                       2
<PAGE>
                           ARKSON NUTRACEUTICALS CORP.

                                 BALANCE SHEETS

<TABLE>
<CAPTION>
                                                              As of               As of
                                                          Dec. 31, 2007       June 30, 2007
                                                          -------------       -------------
<S>                                                         <C>                 <C>
ASSETS

Current Assets
  Cash                                                      $      --           $      --
                                                            ---------           ---------
      Total Assets                                          $      --           $      --

LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)

 Loan from officer/shareholder                                 12,606              12,606
                                                            ---------           ---------
      TOTAL LIABILITIES                                     $  12,606           $  12,606

Stockholders' Equity (Deficit)
  Common stock, $.0001 par value:
   50,000,000 shares authorized,
   10,917,780 shares issued and outstanding
   as of 6/30/2007                                                                  1,092
   10,917,780 shares issued and outstanding
   as of 12/31/2007                                             1,092
  Additional paid in capital                                  122,688             122,688
  Retained Earnings                                                --                  --
  Deficit accumulated during the development stage           (136,386)           (136,386)
                                                            ---------           ---------
      Total Shareholders' Equity (Deficit)                    (12,606)            (12,606)
                                                            ---------           ---------

       TOTAL LIABILITIES & STOCKHOLDERS' EQUITY             $      --           $      --
                                                            =========           =========
</TABLE>


                        See Notes to Financial Statements

                                       3
<PAGE>
                           ARKSON NUTRACEUTICALS CORP.

                             STATEMENT OF OPERATIONS

<TABLE>
<CAPTION>
                                                                                                      From Inception
                                                                                                       Oct. 2, 1998
                                          Six Months Ended                     Years Ended                through
                                              Dec. 31,                           June 30,                 Dec. 31,
                                      2007             2006              2007              2006             2007
                                   -----------      -----------       -----------       -----------      -----------
<S>                                <C>              <C>               <C>               <C>              <C>
Revenue                            $        --      $        --       $        --       $        --      $        --
                                   -----------      -----------       -----------       -----------      -----------
      Total Revenue                         --               --                --                --               --

General & Admin Exps                        --               --             5,000                --          136,610
                                   -----------      -----------       -----------       -----------      -----------

Operating Income (Loss)            $        --      $        --       $    (5,000)      $        --      $  (136,610)

                                   -----------      -----------       -----------       -----------      -----------
Other Income (Expense)
  Interest Income                                                                                                290
  Other Income                                                                                                   194
                                   -----------      -----------       -----------       -----------      -----------
                                                                                                                 484
NET INCOME (LOSS) BEFORE
INCOME TAX BENEFIT                 $        --      $        --       $    (5,000)      $        --      $  (136,610)

INCOME TAX
  Current income tax                                                                                            (260)
  Income tax benefit                                                                                              --
                                   -----------      -----------       -----------       -----------      -----------

NET INCOME (LOSS)                                                     $    (5,000)                          (136,386)
                                   ===========      ===========       ===========       ===========      ===========

Basic and diluted earning
 (Loss) per Share                           --               --           (0.0003)               --
                                   -----------      -----------       -----------       -----------
Weighted average number
 of common shares
 outstanding                        10,917,780       10,917,780        17,417,780        10,917,780
</TABLE>


                        See Notes to Financial Statements

                                       4
<PAGE>
                           ARKSON NUTRACEUTICALS CORP.
                  STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY

<TABLE>
<CAPTION>
                                                                     Accumulated
                                Common Stock           Additional       During         Total
                            ---------------------       Paid in      Development    Stockholders
                            Shares         Amount       Capital         Stage          Equity
                            ------         ------       -------         -----          ------
<S>                       <C>             <C>          <C>            <C>            <C>
Balance, July 1, 2005     10,917,780      $ 1,092      $ 122,688      $(131,386)     $  (7,606)
                          ----------      -------      ---------      ---------      ---------
Common stock issued               --
Net loss for year
 Ended June 30, 2006                                                                        --
                          ----------      -------      ---------      ---------      ---------

Balance, June 30, 2006    10,917,780        1,092        122,688       (131,386)        (7,606)
                          ----------      -------      ---------      ---------      ---------
Common stock issued
 for services             39,000,000        3,900         (3,900)
Common stock cancelled   (39,000,000)      (3,900)         3,900
Net loss for year
 Ended June 30, 2007                                                     (5,000)        (5,000)
                          ----------      -------      ---------      ---------      ---------

Balance, June 30, 2007    10,917,780        1,092        122,688       (136,386)       (12,606)
                          ----------      -------      ---------      ---------      ---------
Common stock issued               --
Net loss for period
 Ended Dec. 31, 2007                                                         --             --
                          ----------      -------      ---------      ---------      ---------

Balance, Dec. 31, 2007    10,917,780      $ 1,092      $ 122,688      $(136,386)     $ (12,606)
                          ==========      =======      =========      =========      =========
</TABLE>

                        See Notes to Financial Statements

                                       5
<PAGE>
                           ARKSON NUTRACEUTICALS CORP.

                             STATEMENT OF CASH FLOWS

<TABLE>
<CAPTION>
                                                                                                       From Inception
                                                                                                        Oct. 2, 1998
                                                 Six Months Ended                 Years Ended              through
                                                     Dec. 31,                       June 30,               Dec. 31,
                                               2007           2006           2007            2006            2007
                                             ---------      ---------      ---------       ---------       ---------
<S>                                          <C>            <C>            <C>             <C>             <C>
CASH FLOWS FROM OPERATING ACTIVITIES
  Net Income (Loss)                          $      --      $      --      $  (5,000)      $      --       $(136,386)
                                             ---------      ---------      ---------       ---------       ---------
Adjustments to reconcile net income
 (loss) to net cash (used in) operations
                                             ---------      ---------      ---------       ---------       ---------
NET CASH PROVIDED BY (USED IN) OPERATIONS           --             --         (5,000)             --        (136,386)
                                             ---------      ---------      ---------       ---------       ---------
CASH FLOWS FROM INVESTING ACTIVITIES

NET CASH PROVIDED BY INVESTING ACTIVITIES           --             --             --              --              --
                                             ---------      ---------      ---------       ---------       ---------
CASH FLOWS FROM FINANCING ACTIVITIES

Loan from officer/shareholder                       --             --          5,000          (2,585)        (42,384)
Loan from related party                             --             --             --              --          54,990
Common stock issuance                               --             --             --              --         123,780
                                             ---------      ---------      ---------       ---------       ---------
NET CASH PROVIDED BY FINANCING ACTIVITIES           --             --          5,000          (2,585)        136,386
                                             ---------      ---------      ---------       ---------       ---------
NET INCREASE (DECREASE)                             --             --             --          (2,585)             --
                                             ---------      ---------      ---------       ---------       ---------
CASH BEGINNING OF PERIOD                            --             --             --           2,585              --
                                             ---------      ---------      ---------       ---------       ---------
CASH END OF PERIOD                           $      --      $      --      $      --       $      --       $      --
                                             =========      =========      =========       =========       =========
Supplemental Disclosures of Cash Flow
Information
  Interest paid                              $      --      $      --      $      --       $      --       $      --
                                             ---------      ---------      ---------       ---------       ---------
  Income taxes paid                          $      --      $      --      $      --       $      --       $     260
                                             ---------      ---------      ---------       ---------       ---------
</TABLE>

                        See Notes to Financial Statements

                                       6
<PAGE>
                           ARKSON NUTRACEUTICALS CORP.
                          (A Development Stage Company)
                          Notes to Financial Statements
              December 31, 2007 and 2006 and June 30, 2007 and 2006


NOTE 1- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

THE COMPANY

Arkson Nutraceuticals Corp. (the "Company"), was incorporated in the state of
Delaware on October 2, 1998. The Company was organized to manufacture and sell a
broad range of natural health food supplements. The Company currently has no
operations and, in accordance with Statement of Financial Accounting Standard
(SFAS) No. 7, "ACCOUNTING AND REPORTING BY DEVELOPMENT STAGE ENTERPRISES," is
considered a development stage enterprise.

Its activities to date have been limited to capital formation, organization,
development of its business plan, and discussions with representatives of
private label manufacturers and wholesale buyers of natural supplements.

CASH AND CASH EQUIVALENTS

For purposes of the statements of cash flows, the Company considers cash
instruments with original maturities of less than three months to be cash
equivalents.

START-UP COSTS

Costs of start-up activities, including organization costs, are expensed as
incurred, in accordance with Statement of Position (SOP) 98-5.

INCOME TAXES

The Company accounts for income taxes under SFAS No. 109, "Accounting for Income
Taxes." This statement requires an asset and liability approach to account for
income taxes. The Company provides deferred income taxes for temporary
differences that will result in taxable or deductible amounts in future years
based on the reporting of certain costs in different periods for financial and
income tax purposes. There is no income tax for the periods ended December 31,
2007 or June 30, 2007 or 2006. The Company has net operating loss carry forward
from prior years that may be used to reduce future taxable income for income tax
purposes.

USE OF ESTIMATES

The presentation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities, disclosure of contingent
assets and liabilities at the date of the financial statements, and the reported
amounts of revenues and expenses during the periods presented. Actual results
may differ significantly from those estimates.

FAIR VALUES OF FINANCIAL INSTRUMENTS

Statement of Financial Accounting Standards No. 107, DISCLOSURES ABOUT FAIR
VALUE OF FINANCIAL INSTRUMENTS, requires disclosure of fair value information
about financial instruments, whether or not recognized in the balance sheet. In
cases where quoted market prices are not available, fair values are based on
estimates using present value or other valuation techniques. Those techniques
are significantly affected by the assumptions used, including the discount rate
and estimates of future cash flows.

                                       7
<PAGE>
                           ARKSON NUTRACEUTICALS CORP.
                          (A Development Stage Company)
                          Notes to Financial Statements
              December 31, 2007 and 2006 and June 30, 2007 and 2006


In that regard, the derived fair value estimates cannot be substantiated by
comparison to independent markets and, in many cases, could not be realized in
immediate settlement of the instruments. Statement No. 107 excludes certain
financial instruments and all non-financial instruments from its disclosure
requirements.

STOCK-BASED COMPENSATION

In accordance with the provisions of SFAS 123, the Company follows the intrinsic
value based method of accounting as prescribed by APB 25, ACCOUNTING FOR STOCK
ISSUED TO EMPLOYEES, for its stock-based compensation.

NEW ACCOUNTING PRONOUNCEMENTS

In February 2006, the Financial Accounting Standards Board ("FASB") issued
Statement of Financial Accounting Standard ("SFAS") No. 155, "Accounting for
Certain Hybrid Financial Instruments--an amendment of FASB Statements No. 133
and 140" ("SFAS No. 155"). The provisions of SFAS No. 155 will be effective for
all financial instruments acquired, issued, or subject to a re-measurement (new
basis) event occurring after the beginning of an entity's first fiscal year that
begins after September 15, 2006. The fair value election provided for in
paragraph 4(c) of this Statement may also be applied upon adoption of this
Statement for hybrid financial instruments that had been bifurcated under
paragraph 12 of Statement 133 prior to the adoption of this Statement. Earlier
adoption is permitted as of the beginning of an entity's fiscal year, provided
the entity has not yet issued financial statements, including financial
statements for any interim period, for that fiscal year. SFAS No. 155 amends
FASB SFAS No. 133, "Accounting for Derivative Instruments and Hedging
Activities" ("SFAS No. 133"), and SFAS No. 140, "Accounting for Transfers and
Servicing of Financial Assets and Extinguishments of Liabilities" ("SFAS No.
140"). SFAS No. 155 resolves issues addressed in SFAS No. 133 Implementation
Issue No. D1, "Application of Statement 133 to Beneficial Interests in
Securitized Financial Assets". This Statement: a) permits fair value
re-measurement for any hybrid financial instrument that contains an embedded
derivative that otherwise would require bifurcation, b) clarifies which
interest-only strips and principal-only strips are not subject to the
requirements of SFAS No.133, c) establishes a requirement to evaluate interests
in securitized financial assets to identify interests that are freestanding
derivatives or that are hybrid financial instruments that contain an embedded
derivative requiring bifurcation, d) clarifies that concentrations of credit
risk in the form of subordination are not embedded derivatives, and e) amends
SFAS No.140 to eliminate the prohibition on a qualifying special purpose entity
from holding a derivative financial instrument that pertains to a beneficial
interest other than another derivative financial instrument. The Company is
currently evaluating the impact of adopting SFAS No. 155.

In March 2006, the FASB issued SFAS No. 156, "Accounting for Servicing of
Financial Assets--an amendment of FASB Statement No. 140" ("SFAS No. 156"). An
entity shall adopt this Statement as of the beginning of its first fiscal year
that begins after September 15, 2006. Earlier adoption is permitted as of the
beginning of an entity's fiscal year, provided the entity has not yet issued
financial statements, including interim financial statements, for any period of
that fiscal year. The effective date of this Statement is the date that an
entity adopts the requirements of this Statement. SFAS No. 156 amends SFAS No.
140, "Accounting for Transfers and Servicing of Financial Assets and
Extinguishments of Liabilities", with respect to the accounting for separately
recognized servicing assets and servicing liabilities. This Statement: a)
requires an entity to recognize a servicing asset or servicing liability each
time it undertakes an obligation to service a financial asset by entering into a
servicing contract in any of the following situations, b) requires all
separately recognized servicing assets and servicing liabilities to be initially

                                       8
<PAGE>
                           ARKSON NUTRACEUTICALS CORP.
                          (A Development Stage Company)
                          Notes to Financial Statements
              December 31, 2007 and 2006 and June 30, 2007 and 2006


measured at fair value, if practicable, c) permits an entity to choose between
two subsequent measurement methods for each class of separately recognized
servicing assets and servicing liabilities, d) at its initial adoption, permits
a one-time reclassification of available-for-sale securities to trading
securities by entities with recognized servicing rights, without calling into
question the treatment of other available-for-sale securities under SFAS No.
115, provided that the available-for-sale securities are identified in some
manner as offsetting the entity's exposure to changes in fair value of servicing
assets or servicing liabilities that a servicer elects to subsequently measure
at fair value, and e) requires separate presentation of servicing assets and
servicing liabilities subsequently measured at fair value in the statement of
financial position and additional disclosures for all separately recognized
servicing assets and servicing liabilities. The Company is currently evaluating
the impact of adopting SFAS No. 156.

In July 2006, the FASB issued FASB Interpretation No. 48 ("FIN 48"), "Accounting
for Uncertainty in Income Taxes - an interpretation of FASB Statement No. 109".
FIN 48 requires that the Company recognize in the consolidated financial
statements the impact of a tax position that is more likely than not to be
sustained upon examination based on the technical merits of the position. The
provisions of FIN No. 48 will be effective for the Company beginning in the
March 2007 quarter, with the cumulative effect of the change in accounting
principle recorded as an adjustment to opening retained earnings. The Company is
currently evaluating the impact of adopting FIN No. 48.

In September 2006, the FASB issued SFAS No. 157, "Fair Value Measurements"
("SFAS No. 157"). SFAS No. 157 is effective for financial statements issued for
fiscal years beginning after November 15, 2007, and interim periods within those
fiscal years. Earlier application is encouraged, provided that the reporting
entity has not yet issued financial statements for that fiscal year, including
any financial statements for an interim period within that fiscal year. The
Company is currently evaluating the impact of adopting SFAS No. 157.

In September 2006, the FASB issued SFAS No. 158, "Employers' Accounting for
Defined Benefit Pension and Other Postretirement Plans" ("SFAS No. 158"). SFAS
No. 158 provides different effective dates for the recognition and related
disclosure provisions and for the required change to a fiscal year-end
measurement date. Also, the effective date of the recognition and disclosure
provisions differs for an employer that is an issuer of publicly traded equity
securities from one that is not. For purposes of this Statement, an employer is
deemed to have publicly traded equity securities if any of the following
conditions is met: a) the employer has issued equity securities that trade in a
public market, which may be either a stock exchange (domestic or foreign) or an
over-the-counter market, including securities quoted only locally or regionally,
b) the employer has made a filing with a regulatory agency in preparation for
the sale of any class of equity securities in a public market, or c) the
employer is controlled by an entity covered by (a) or (b). An employer with
publicly traded equity securities shall initially apply the requirement to
recognize the funded status of a benefit plan and the disclosure requirements as
of the end of the fiscal year ending after December 15, 2006. Application as of
the end of an earlier fiscal year is encouraged; however, early application
shall be for all of an employer's benefit plans. The requirement to measure plan
assets and benefit obligations as of the date of the employer's fiscal year-end
statement of financial position (paragraphs 5, 6, and 9) shall be effective for
fiscal years ending after December 15, 2008, and shall not be applied
retrospectively. Earlier application is encouraged; however, early application
shall be for all of an employer's benefit plans. An employer with publicly
traded equity securities shall initially apply the requirement to recognize the
funded status of a benefit plan (paragraph 4) and the disclosure requirements

                                       9
<PAGE>
                           ARKSON NUTRACEUTICALS CORP.
                          (A Development Stage Company)
                          Notes to Financial Statements
              December 31, 2007 and 2006 and June 30, 2007 and 2006


(paragraph 7) as of the end of the fiscal year ending after December 15, 2006.
The Company is currently evaluating the impact of adopting SFAS No. 158.

NOTE 2 - STOCKHOLDERS' EQUITY

COMMON STOCK

The Company has authorized fifty million (50,000,000) shares of common stock,
having one hundredth of a cent ($0.0001) par value per share.

On October 2, 1998 the Company issued a total of 9,250,000 shares to its three
founders for services rendered in connection with the organization of the
Company. Also in 1998 the Company issued 600,000 shares of common stock for
cash, net of offering costs, in the amount of $6,000. Also in 1998 the Company
issued 1,000,000 shares of common stock for cash, net of offering costs, in the
amount of $50,000. In 1999 the Company issued 16,000 shares of common stock for
cash, net of offering costs, in the amount of $16,000.

In 2000 the Company issued 50,000 shares of common stock for cash, net of
offering costs, in the amount of $50,000, and also issued 1,780 shares for
services valued at $1,780.

In the first quarter of 2007 the Company issued 39,000,000 shares of common
stock to its president in exchange for services, however this issuance was
cancelled before the share certificate was prepared.

Thus, as of December 31, 2007 there were 10,917,780 shares of common stock
issued and outstanding.

NOTE 3 - EARNINGS PER SHARE

There were no earnings and losses for the periods ended December 31, 2007 and
2006. There was a loss of $5,000 during the year ended June 30, 2007. Therefore
earnings (losses) per share for each of the quarters reported herein $0.00, and
losses for the year ended June 30, 2007 was approximately $(0.0003) per share.

For the periods ended December 31, 2007 and 2006 and the years ended June 30,
2007 and 2006, and for the period October 2, 1998 (inception) to December 31,
2007 there were no shares issuable under stock options, warrants, or rights.
Therefore, diluted earnings per share were the same as basic earnings per share
at all times.

NOTE 4 - INCOME TAXES

At June 30, 2007, the Company has a net operating loss carryforward for tax
purpose of approximately $136,386 which expires through the year 2018. The
Internal Revenue Code contains provisions which may limit the loss carryforward
available if significant changes in stockholder ownership of the Company occur.

There were no provisions for income taxes for the years ended June 30, 2007 and
2006 or for the periods ended December 31, 2007 and 2006.

                                       10
<PAGE>
                           ARKSON NUTRACEUTICALS CORP.
                          (A Development Stage Company)
                          Notes to Financial Statements
              December 31, 2007 and 2006 and June 30, 2007 and 2006


NOTE 5 - RELATED PARTY TRANSACTIONS

LOANS PAYABLE

Between October 2, 1998 (Inception) and December 31, 2003 certain officers and
shareholders made a number of non-interest bearing loans to the Company totaling
$54,990 and received principal repayments of those loans totaling $44,800. As of
December 31, 2003, 2004, and 2005 one shareholder was owed the principal sum of
$10,190. On February 6, 2006 that shareholder was repaid $2,585 of the sum owing
to him. In May that shareholder loaned an additional $5,000 to the Company. As a
result, there was a liability of $12,606 owed to a shareholder as of December
31, 2007.

NOTE 6 - GOING CONCERN

The accompanying financial statements have been prepared assuming that the
Company will continue as a going concern. The Company's financial position and
operating results raise substantial doubt about the Company's ability to
continue. The Company has had no operating revenue since inception and is
currently not operating.

The ability of the Company to continue as a going concern is dependent upon
developing sales and obtaining additional capital and financing. The financial
statements do not include any adjustments that might be necessary if the Company
is unable to continue as a going concern.

NOTE 7- SUBSEQUENT EVENT

There is no subsequent event to disclose since the end of the second quarter on
December 31, 2007.

NOTE 8 - COMMITMENT AND CONTIGENTCY

There is no commitment or contingency to disclose during the years ended June
30, 2007 and 2006 or the periods ended December 31, 2007 and 2006.

                                       11
<PAGE>
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
        RESULTS OF OPERATIONS

     The discussion contained herein contains "forward-looking statements" that
involve risk and uncertainties. These statements may be identified by the use of
terminology such as "believes," "expects," "may," "should" or anticipates" or
expressing this terminology negatively or similar expressions or by discussions
of strategy. The cautionary statements made in this Form 10QSB should be read as
being applicable to all related forward-looking statements wherever they appear
in this Form 10QSB. Our actual results could differ materially from those
discussed in this report.

     Arkson Nutraceuticals Corp. (the "Company") was incorporated on October 2,
1998 under the laws of the State of Delaware. The Company intended to engage in
the manufacture and sale of a broad range of proprietary natural health food
supplement products. The Company began to negotiate licenses with developers of
natural health food supplements approximately one month after incorporation. The
Company also entered negotiations with various wholesale buyers of such products
and with finance organizations. These explorations and negotiations continued at
a high level for a period of approximately two years after incorporation, and at
a slower pace for one additional year. However, no such licenses or contracts
materialized.

     As a result of the Company's failure to generate sales it operated at a
loss. By June 30, 2001 all funds raised by the sale of shares had been expended,
and the Company thereafter became dormant. From July 1, 2001 until the present,
it was inactive and could be deemed to be a so-called "shell" company, whose
only purpose at this time is to determine and implement a new business purpose.
As a "shell" company, our sole purpose at this time is to locate and consummate
a merger or acquisition with a private entity. We have not yet identified any
company or companies which we hope to merge with or acquire.

FINANCIAL CONDITION.

     Our auditor's going concern opinion for prior years ended and the notation
in the financial statements indicate that we do not have significant cash or
other material assets and that we are relying on advances from stockholders,
officers and directors to meet limited operating expenses.

LIQUIDITY AND OPERATIONAL RESULTS.

     The Company has no current operating history and does not have any revenues
or earnings from operations. The Company has no assets or financial resources.
We will, in all likelihood, sustain operating expenses without corresponding
revenues, at least until the closing of a merger with or acquisition of an
operating business.

     We are dependent upon our officers to meet any DE MINIMIS costs that may
occur. Our two officers and directors have agreed to provide the necessary
funds, without interest, for the Company to comply with the Securities Exchange
Act of 1934, as amended, provided that they are officers and directors of the
Company when the obligation is incurred. All advances are interest-free.

LIQUIDITY.

     As of December 31, 2007, we had no assets and liabilities of $12,606 and we
had an accumulated deficit of $136,386. As of June 30, 2006, our last year end,
we also had no assets and liabilities of $12,606 and we had an accumulated
deficit of $136,386.

     We have had no revenues from inception through June 30, 2007 and we had no
revenues for the period ended December 31, 2007. We have a loss from inception
through June 30, 2007 of $136,386 and a loss from inception through December 31,
2007 of the same amount - $136,386.

                                       12
<PAGE>
ACCOUNTING FOR A BUSINESS COMBINATION.

     In July 2001, the Financial Accounting Standards Board issued Statement of
Financial Accounting Standards "SFAS" No. 141, "Business Combinations" and SFAS
No. 142, "Goodwill and Other Intangible Assets." SFAS No. 141 requires business
combinations initiated after June 30, 2001 to be accounted for using the
purchase method of accounting, and broadens the criteria for recording
intangible assets separate from goodwill. Recorded goodwill and intangibles will
be evaluated against these new criteria and may result in certain intangibles
being subsumed into goodwill, or alternatively, amounts initially recorded as
goodwill may be separately identified and recognized apart from goodwill. SGAS
No. 142 requires the use of a non-amortization approach to account for purchased
goodwill and certain intangibles. Under a non-amortization approach, goodwill
and certain intangibles is more than its fair value. Goodwill is the excess of
the acquisition costs of the acquired entity over the fair value of the
identifiable net assets acquired. The Company is required to test goodwill and
intangible assets that are determined to have an indefinite life for impairments
at least annually. The provisions of SFAS No. 142 require the completion of an
annual impairment test with any impairment recognized in current earnings. The
provisions of SFAS No. 141 and SFAS No. 142 may be applicable to any business
combination that we may enter into in the future.

     We have also been informed that most business combinations will be
accounted for as a reverse acquisition with us being the surviving registrant.
As a result of any business combination, if the acquired entity's shareholders
will exercise control over us, the transaction will be deemed to be a capital
transaction where we are treated as a non-business entity. Therefore, the
accounting for the business combination is identical to that resulting from a
reverse merger, except no goodwill or other intangible assets will be recorded.
For accounting purposes, the acquired entity will be treated as the accounting
acquirer and, accordingly, will be presented as the continuing entity.

ITEM 3. QUALITATIVE AND QUANTITATIVE DISCLOSURES ABOUT MARKET RISK.

     The Company has not considered nor conducted any research concerning
qualitative and quantitative market risk.

ITEM 4. EVALUATION OF DISCLOSURE ON CONTROLS AND PROCEDURES.

     Based on an evaluation of our disclosure controls and procedures as of the
end of the period covered by this Form 10QSB (and the financial statements
contained in the report), our president and treasurer have determined that the
our current disclosure controls and procedures are effective.

     There have not been any changes in our internal control over financial
reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act) or
any other factors during the quarter covered by this report, that have
materially affected, or are reasonably likely to materially affect our internal
control over financial reporting.

                                     PART II
                                OTHER INFORMATION

ITEM 1 - LEGAL PROCEEDINGS

None

ITEM 2 - CHANGES IN THE RIGHTS OF THE COMPANY'S SECURITY HOLDERS

None

ITEM 3 - DEFAULTS BY THE COMPANY ON ITS SENIOR SECURITIES

None

                                       13
<PAGE>
ITEM 4 - SUBMISSION OF MATTER TO VOTE OF SECURITY HOLDERS

None

ITEM 5 - OTHER INFORMATION

AUDIT COMMITTEE.

     Our board of directors has not established an audit committee. In addition,
we do not have any other compensation or executive or similar committees. We
will not, in all likelihood, establish an audit committee until such time as the
Company generates a positive cash flow of which there can be no assurance. We
recognize that an audit committee, when established, will play a critical role
in our financial reporting system by overseeing and monitoring management's and
the independent auditors' participation in the financial reporting process. At
such time as we establish an audit committee, its additional disclosures with
our auditors and management may promote investor confidence in the integrity of
the financial reporting process.

     Until such time as an audit committee has been established, the full board
of directors will undertake those tasks normally associated with an audit
committee to include, but not by way of limitation, the (i) review and
discussion of the audited financial statements with management, and (ii)
discussions with the independent auditors the matters required to be discussed
by the Statement On Auditing Standards No. 61 and No. 90, as may be modified or
supplemented.

CODE OF ETHICS.

     We have adopted a code of ethics that applies to our principal executive
officer, principal financial officer, principal accounting officer and persons
performing similar functions. The code of ethics will be posted on the investor
relations section of the Company's website in the event that we have a website.
At such time as we have posted the code of ethics on our website, we intend to
satisfy the disclosure requirements under Item 10 of Form 8-K regarding an
amendment to, or waiver from, a provision of the code of ethics by posting such
information on the website.

ITEM 6 - EXHIBITS AND REPORTS ON FORM 8-K

     A report on Form 8-K was filed on July 25, 2007 reporting on Item 5.02, a
change in Directors and Management and Item 5.03, a change in the Company's
fiscal year. That report on Form 8-K is incorporated herein by reference.

     The following exhibits are filed with this report:

     31.1 Rule 13a-14(a)/15d-14(a) - Certification of Chief Executive Officer.

     31.2 Rule 13a-14(a)/15d-14(a) - Certification of Chief Financial Officer.

     32.1 Section 1350 Certification - Chief Executive Officer.

     32.2 Section 1350 Certification - Chief Financial Officer.

                                       14
<PAGE>
                                      SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

Date: February 12, 2008           ARKSON NUTRACEUTICALS CORP.


                                  By: /s/ Robert Auduon
                                       ---------------------------------
                                       Robert Auduon
                                       President and Director


                                  By: /s/ Agatha Auduon
                                       ---------------------------------
                                       Agatha Auduon
                                       Treasurer and Director

                                       15